Typhoid vaccine study seeks immune clues
NCT ID NCT03971669
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gives healthy adults the licensed oral typhoid vaccine (Vivotif) and collects blood, saliva, and stool samples over up to eight years. Researchers want to learn how the vaccine triggers protective immune responses, which could help design better vaccines for typhoid and other gut infections. The study involves 150 volunteers and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vivotif (oral typhoid vaccine)
- What this could lead to
- If successful, this could help researchers develop better vaccines for typhoid and other gut infections.
- What could go wrong
- This is an observational study focused on immune responses, not a treatment trial. Results may not directly lead to new vaccines or therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2004
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years and older * Good general health as determined by a screening evaluation within 28 days before blood donation * Informed, written consent Exclusion Criteria: * History of any of the following medical illnesses: * Diabetes * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ) * Heart disease (Hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease - dyspnea, angina, orthopnea) * Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis) * Current drug or alcohol abuse * Active ulcer disease or ongoing intestinal condition * Treatment for anemia in last 6 months * Currently being treated with anti-malarial drugs * Any of the following laboratory abnormalities detected during medical screening: * WBC \<0.81 x LLN or \> 1.09 x ULN * Hemoglobin \<0.91 x LLN or \>1.18 x ULN (women) or \<0.92 x LLN or \>1.18 x ULN (men) * Platelet count \<0.8 x LLN or \> 1.2 x ULN * (For leukopheresis or blood unit donations, the following lab values are exclusionary: * WBC \<3.5 or \>11 x 103/mm3; * Hemoglobin \<12.5 or \>18 g/dl * Platelet count \<150 or \>500 x 103/mm3) * SGOT or SGPT \>1.5 times normal * Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen * Positive serology for hepatitis B core antibody * Poor peripheral venous access for blood donation * Positive RPR * Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study. * Positive urine pregnancy test (HCG) on day of vaccination. Prior to each blood donation -females with menstrual history consistent with pregnancy. Pregnant women will not be enrolled, because immunological changes that occur during pregnancy may interfere with laboratory assays.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Risk reduction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Maryland, Baltimore, Center for Vaccine Development and Global Health
RECRUITINGBaltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A nudge in the mailbox: could a letter boost flu shots for millions at risk?
- Seeing the invisible: could live air quality displays spark healthier choices?
- Lifestyle makeover may shield aging brains
- AI-Powered health coach in your pocket: could this app prevent disease?
- AI boosts cataract surgery precision for severely nearsighted patients
- Mountain rescue under the microscope: does thin air hurt patient care?